에 대한 최신 뉴스 Enovix (NASDAQ:ENVX) 주식

ENOVIX CORP

Enovix

Enovix Corp is engaged in designing, developing, manufacturing, and commercializing Lithium-ion, or Li-ion, battery cells. It uses BreakFlow and Encapsulation technologies to manufacture high capacity and resilient batteries. The company's product portfolio comprises power disc batteries, flexible lithium-ion polymer batteries, superior lithium-ion polymer batteries, active silicon lithium-ion cells, and others. Geographically, the company generates maximum revenue from its customers in South Korea, followed by Switzerland, Norway, the United States, Taiwan, and other regions.

stpckchartbenzingaai2023_stock_market_trading_setup_close_up_of_multipl_8fe49d0f-1b96-4300-8432-bd41086c3559_1

CVNA

ENVX

GRAB

PLTR

TSLA

수요일(19일) 미국 주요 지수는 상승 마감했다 소매 투자자와 트레이더들의 주목을 받은 상위 종목은 다음과 같다. 팔란티어, 카바나, 에노빅스, 그랩 및 테슬라

수요일 주목받은 주식: 팔란티어, 카바나, 에노빅스, 그랩 및 테슬라

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Equities

News

Markets

FUBO

월요일 주목받은 주식: 메타, 트럼프 미디어, 푸보TV, 이노빅스 및 테슬라

Global

After-Hours Center

Movers

Tech

이노빅스(NASDAQ:ENVX)의 주식은 회사가 말레이시아 Fab2의 현장 수용 테스트를 완료했다고 발표한 후 월요일 시간외 거래에서 약 10% 급등했다. 무슨 일이 있었나: 이노빅스(Enovix)는 지난 12월 말에 Fab2의 고용량 제조 라인에 대한 현장 수용 테스트를 완료했다고 밝혔다. 이 배터리 제조 회사는 올해 말 대량 생산을 시작할 계획이다.

이노빅스 주식이 월요일 시간외 거래에서 약 10% 급등: 무슨 일이?

Enovix Corp

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.27</td>
<td align="right">0.30</td>
<td align="right">0.73</td>
<td>1.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">216.37</td>
<td align="right">1.36</td>
<td align="right">0.63</td>
<td>4.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">106.96</td>
<td align="right">0.53</td>
<td align="right">0.49</td>
<td>105</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">146.00</td>
<td align="right">0.66</td>
<td align="right">0.45</td>
<td>673</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">81.45</td>
<td align="right">0.28</td>
<td align="right">0.34</td>
<td>3.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">86.03</td>
<td align="right">0.28</td>
<td align="right">0.32</td>
<td>35.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">251.60</td>
<td align="right">0.53</td>
<td align="right">0.21</td>
<td>14.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">87.96</td>
<td align="right">0.18</td>
<td align="right">0.20</td>
<td>880</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">134.47</td>
<td align="right">0.25</td>
<td align="right">0.18</td>
<td>3.9K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">51.85</td>
<td align="right">0.06</td>
<td align="right">0.11</td>
<td>292.6K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">80.15</td>
<td align="right">-0.02</td>
<td align="right">-0.03</td>
<td>1.5K</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For June 27, 2025

U.S. stock futures were higher this morning, with the Dow futures gaining over 100 points on Friday.
Shares of Concentrix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) fell sharply in today's pre-market trading after the company posted mixed <a href="https://www.benzinga.com/quote/CNXC/earnings">second-quarter results</a>.
Concentrix reported quarterly earnings of $2.70 per share, which missed the analyst consensus estimate of $2.75. Quarterly revenue came in at $2.42 billion, which beat the Street estimate of $2.38 billion
Concentrix shares dipped 8% to $50.70 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul class="wp-block-list">
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) declined 14.2% to $12.83 in pre-market trading after the company announced an $85 million public offering.</li>
<li>Critical Metals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRML#NASDAQ">CRML</a>) fell 14.2% to $3.14 in pre-market trading after surging more than 32% on Thursday.</li>
<li>AdaptHealth Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) fell 8.6% to $8.61 in pre-market trading after gaining around 5% on Thursday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) declined 8.4% to $11.65 in pre-market trading.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) fell 5.1% to $22.60 in pre-market trading.</li>
<li>OMS Energy Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMSE#NASDAQ">OMSE</a>) fell 4.6% to $6.80 in pre-market trading.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/46115042/top-2-tech-and-telecom-stocks-you-may-want-to-dump-in-june">Top 2 Tech And Telecom Stocks You May Want To Dump In June</a> </li>
</ul>
Photo via Shutetrstock

Trading Ideas

AHCO

CNXC

CRMD

CRML

OMSE

USAR

Concentrix Posts Downbeat Earnings, Joins CorMedix And Other Big Stocks Moving Lower In Friday's Pre-Market Session

RBC Capital analyst Drew McReynolds reiterates Corus Entertainment (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CJR#TSX">CJR</a>) with a Sector Perform and maintains C$0.2 price target.

Price Target

Reiteration

Analyst Ratings

TSX:CJR

TSX:CJR/B

RBC Capital Reiterates Sector Perform on Corus Entertainment, Maintains C$0.2 Price Target

Select Medical Corporation today announced it signed a membership interest purchase agreement with Ballad Health to jointly operate Select Specialty Hospital – Tri-Cities, a critical illness recovery hospital in Kingsport, Tenn. The facility, licensed as long-term acute care, will be a hospital-in-hospital located in Ballad Health's Indian Path Community Hospital.&nbsp;
Select Medical will serve as the majority owner and managing partner of the 46-bed joint venture hospital with Ballad Health. The hospital, which is currently owned and operated by Select Medical, will relocate from Ballad Health's Bristol Regional Medical Center to Indian Path Community Hospital following regulatory approval.

Select Medical Signs Membership Interest Purchase Agreement With Ballad Health To Jointly Operate Select Specialty Hospital – Tri-Cities

RSLS

ReShape Lifesciences Regains Nasdaq Compliance Under Minimum Stockholders Equity Requirement

On June 25, 2025, Ralliant Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RALW#NYSE">RALW</a>), a spin-off of Fortive Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTVW#NYSE">FTVW</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>) <a href="https://gsbresearch.com/product/spinoff-analysis-fortive-and-ralliant-begin-when-issued-trading/">commenced when-issued trading</a> on the NYSE. 
Earlier on September 4, 2024, FTV announced plans to separate its Precision Technologies business into a separate publicly listed company, Ralliant Corp, via a tax-free spin-off transaction. The parent will retain the Intelligent Operating Solutions (IOS) and Advanced Healthcare Solutions (AHS) business segments, boasting a portfolio with 50% recurring revenue. We see the spin-off as a move to streamline operations and accelerate business growth, thereby unlocking value for shareholders. The spin-off will allow Fortive to focus on high-growth, high-margin businesses in software and connected devices. The Precision Technologies business is more capital-intensive and has stable but slower growth than the parent. The separation will allow Ralliant to allocate capital and resources more efficiently towards its needs, such as R&amp;D for advanced instrumentation or acquisitions within its niche.
The record date for the distribution of Ralliant shares was June 16, 2025. Each FTV shareholder will receive 1 share of Ralliant for every 3 shares of FTV held as of the record date. The regular-way trading will begin on June 30, 2025. Ralliant will trade under the ticker ‘RAL' and Fortive (ex Ralliant) will continue to trade under the ticker ‘FTV'. The spin-off of Ralliant will be effective on June 28. The transaction is intended to qualify as tax-free to Fortive shareholders.
Following the completion, Olumide Soroye, the current leader of Fortive's intelligent operations division, will assume the position of CEO. Meanwhile, Tami Newcombe, the current overseer of the Precision Technologies and Advanced Health-Care units, will take charge of Ralliant Corp.
As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. RAL will assume debt to pay the cash dividend to FTV and commence its journey as a standalone company with a leverage of 1.9x.
INVESTMENT HIGHLIGHTS
Fortive (ex Ralliant)
Post the separation, Fortive will comprise the portfolio brands such as Accruent, Fluke, Gordian, Censis, Provation, currently operating under Fortive's two business segments – Intelligent Operating Solutions (iOS) and Advanced Healthcare Solutions (AHS). The two business segments generate nearly 50% recurring revenue and have demonstrated lower volatility across cycles.
FTV (ex Ralliant) will be $4 billion in revenues, with 65% adjusted gross margins and 29% adjusted EBITDA margins. The business generated about $1 billion in free cash flow over the last twelve months with an adjusted net income to FCF conversion of more than 100%. Over the last five years, it has delivered 4% core revenue CAGR.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="906" height="117" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png" alt="" class="wp-image-14985" style="width:850px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8.png 906w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-300x39.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27103225/image-8-768x99.png 768w" sizes="(max-width: 906px) 100vw, 906px" /></figure>
Intelligent Operating Solutions (IOS). IOS is Fortive's largest segment, accounting for nearly 70% of the revenue post spin-off. It houses flagship brands such as Fluke (electrical and industrial test tools), Industrial Scientific (gas detection and worker safety), Accruent and Gordian (enterprise asset management), and ServiceChannel (facility maintenance SaaS platform). The segment serves diverse end markets predominantly industrial, government, retail &amp; consumer. Geographically, U.S. accounts for the largest revenue contribution at 56% of total, followed by Europe at 17% and China at 8%.
Advanced Healthcare Solutions (AHS). The AHS segment supplies critical workflow solutions critical for patient care. This includes instrument sterilization solutions, instrument tracking, biomedical test tools, radiation detection and safety monitoring, and end-to-end clinical productivity software and solutions. The AHS segment has a recurring revenue base at nearly 80% with adjusted EBITDA margins in high 20s. The addressable market across AHS verticals exceeds $10 billion, with low single-digit to mid-single digit growth potential.
Capital Structure. As part of the transaction, FTV (ex RAL) will receive $1.15 billion in dividend from Ralliant Corp. Of which, $700 million will be used to repay debt. The remaining will be used for share buyback under its $550 million share repurchase authorization program. Pro forma debt post spin-off is expected to be $3.2 billion, with cash &amp; cash equivalents at $1.2 billion. Based on TTM Q1 2025 adjusted EBITDA, leverage is 2.7x, with the target to bring it down to 2.5x in the next 12-18 months.
Ralliant Corp
Ralliant Corp will include the Precision Technologies business comprising a portfolio of brands such as Gems, Tektronix, Setra, Qualitrol, among others. It offers advanced instrumentation and precision measurement solutions to aerospace, defense, electronics, automotive, and industrial manufacturing.
The Company will operate via two segments &#8211; Test and Measurement (~56% of total sales) and Sensors and Safety Systems (44% of total sales).
Capital Structure
As part of the transaction, Ralliant will issue new debt of $1.15 billion via a term loan. The proceeds will be used to fund the cash distribution to Fortive. Pro forma cash post the transaction will be $150 million, implying a net debt of $1.0 billion. Additionally, RAL will have access to a total liquidity of $900 million comprising an undrawn revolving credit facility of $750 million and $150 million in undrawn term loans. Based on TTM Q1 2025 adjusted EBITDA, leverage is 1.9x, which is within the Company's target range of 1.5x-2.0x.
Financial Outlook
FTV (ex RAL)
We expect FTV (ex RAL) to deliver revenue growth of 3.6% in FY25. We expect margins to expand, supported by higher mix of recurring revenue and operating leverage. As such, we model EBITDA margins of 29% in FY25, up 50 bps YOY. The combination of solid revenue growth and margin expansion should drive EPS higher. We model adjusted EPS of $2.56 in FY25, up 6% YOY.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="710" height="148" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png" alt="" class="wp-image-14987" style="width:506px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9.png 710w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104037/image-9-300x63.png 300w" sizes="(max-width: 710px) 100vw, 710px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Ralliant Corp (RAL)
We expect RAL to deliver revenue growth of 3.5% in FY25 and 4.0% in FY:26. We expect adjusted EBITDA to grow faster than revenue, implying margin expansion. As such, we model EBITDA margins of 23.7% in FY25 and 23.9% in FY:26. We forecast adjusted EPS of $3.40 in FY25 and $3.60 in FY26.
<figure class="wp-block-image size-full is-resized"><img loading="lazy" decoding="async" width="704" height="170" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png" alt="" class="wp-image-14988" style="width:501px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10.png 704w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/06/27104157/image-10-300x72.png 300w" sizes="(max-width: 704px) 100vw, 704px" /><figcaption class="wp-element-caption">Source: GSBR Research Estimates, Company filings</figcaption></figure>
Valuation
FTV (ex RAL) 
We value FTV (ex RAL) using the EV/EBITDA multiple. We value IOS segment at 19x 2026E adjusted EBITDA of $1,049 million, and ASH segment at 12.6x 2026E adj. EBITDA of $395 million, in line with the peer group average. Corporate expense is valued at 12x. We use debt of ~$3.2 billion and cash of $1.2 billion (factoring in ~$1.15 billion of proceeds from RAL which will be used to pare debt). We assume ~339 million shares outstanding. Our 12-month price target is $62.70.
Ralliant Corp (RAL) 
We value RAL using the EV/EBITDA multiple. We apply a multiple of 12.4x 2026E adjusted EBITDA of $557 million, at a discount to the peer group average given RAL's lower growth and margin profile and higher debt. We assume ~113 million shares outstanding. Our 12-month price target is $52.40.

Conclusion: Of the two, Fortive (ex RAL) seems a better investment opportunity and could attract higher investor interest given its higher margin profile, reducing debt and share buyback program.

Long Ideas

Opinion

Fortive Corporation Common Stock When-Issued

FTVW

RALW

Fortive Or Its Spin-Off Ralliant: Which Stock Is A Better Buy?

WETH

WeTouch Secures Nasdaq Extension To File Delinquent 10-K And 10-Q Reports

RBC Capital analyst Irene Nattel reiterates Alimentation Couche-Tard (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATD#TSX">ATD</a>) with a Outperform and maintains C$94 price target.

TSX:ATD

RBC Capital Reiterates Outperform on Alimentation Couche-Tard, Maintains C$94 Price Target

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced that it has entered into definitive agreements in a registered direct offering with a single institutional investor for the purchase and sale of approximately $17.2 million of shares of Common Stock and pre-funded warrants at a price of $7.50 per share of Common Stock. Upon closing of the offering, the Company will have fully utilized its shelf registration statement.

Offerings

Cyngn Announces $17.2M Registered Direct Offering At $7.50/Shr

WIIM

Alpha Pro Tech shares are trading higher after the company's board authorized a $2 million expansion of its share repurchase program.

Buybacks

Alpha Pro Tech Board Authorizes $2M Expansion Of Share Repurchase Program

In a potential game-changer for the cryptocurrency mining sector, Morgan Stanley has forecasted that CoreWeave Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWV#NASDAQ">CRWV</a>) proposed acquisition of Core Scientific Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) could boost the Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) miner&#8217;s market capitalization by an impressive $2.8 billion.
What Happened: This Morgan Stanley analysis was shared by Eric Jackson from EMJ Capital amid renewed takeover discussions between the two companies, as reported by the Wall Street Journal, with a deal possibly finalizing within weeks if negotiations proceed smoothly.
&#8220;While the potential terms of a deal were not released, the estimated profits from the current contracts exceed Core Scientific's market cap by ~$2.8B,&#8221; said Jackson in his X post, quoting Morgan Stanley.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Morgan Stanley on the potential <a href="https://twitter.com/search?q=%24CRWV&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CRWV</a> &#8211; <a href="https://twitter.com/search?q=%24CORZ&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$CORZ</a> deal: While the potential terms of a deal were not released, the estimated profits from the current contracts exceed Core Scientific's market cap by ~$2.8B (with CORZ market cap at ~$4.95B today).
&mdash; Eric Jackson (@ericjackson) <a href="https://twitter.com/ericjackson/status/1938421603253235836?ref_src=twsrc%5Etfw">June 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Core Scientific, currently valued at approximately $4.87 billion, rejected $5.75 per share offer from CoreWeave a year ago. The company operates one of North America's largest digital infrastructure platforms focused on bitcoin mining and hosting.
The company's strategic 12-year hosting partnership with CoreWeave, which provides 590 MW of capacity across 12 contracts valued at $10 billion, underpins this growth.
&#8220;Core Scientific receives a 75%-80% profit margin on the CoreWeave contract, which implies that Core Scientific receives a profit of ~$7.75bn at the midpoint,&#8221; Jackson highlighted in another post.
See Also: <a href="https://www.benzinga.com/markets/equities/25/06/46108861/microsoft-is-playing-chess-and-others-are-playing-checkers-dan-ives-says-msft-could-be-a-5-trillion-company-in-18-months">Microsoft Is &#8216;Playing Chess, And Others Are Playing Checkers:&#8217; Dan Ives Says MSFT Could Be A $5 Trillion Company In 18 Months</a>
Why It Matters: CoreWeave, a $75.87 billion cloud infrastructure giant serving AI workloads for clients like Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), is funding up to $750 million in data center build-outs, with Core Scientific contributing just $104 million.
&#8220;Core Scientific receives a 75%-80% profit margin on the CoreWeave contract, which implies that Core Scientific receives a profit of ~$7.75bn at the midpoint,&#8221; explained Jackson.
Price Action: CRWV shares were up 1.97% in premarket on Friday and ended 0.89% lower on Thursday. It has risen by 295.20% since its listing in March.
Benzinga Edge Stock Rankings shows that CRWV had a stronger price trend over the short, medium, and long term. Its value ranking was poor at the 9.72nd percentile. The details are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="156" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-1024x156.png" alt="" class="wp-image-964838" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-1024x156.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-300x46.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new-768x117.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27083111/CRWV-EDGE-new.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
CORZ shares were up 7.89% in premarket on Friday and ended 33.01% higher on Thursday. It has risen by 12.98% on a year-to-date.
Benzinga Edge Stock Rankings shows that CORZ had a stronger price trend over the short, medium, and long term. Its momentum ranking was solid; however, its value ranking was poor at the 16.3rd percentile. The details of other metrics are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="162" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-1024x162.png" alt="" class="wp-image-964835" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-1024x162.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-300x47.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE-768x121.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/27082907/CORZ-EDGE.png 1033w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, were higher in premarket on Thursday. The SPY was up 0.39% at $614.24, while the QQQ advanced 0.46% to $548.73, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/46112471/ross-gerber-touts-an-idea-to-cut-deficit-by-trillions-of-dollars-let-the-tax-cuts-e">Ross Gerber Touts An Idea To Cut Deficit By Trillions Of Dollars: &#8216;Let The Tax Cuts Expire And Full SALT Come Back&#8217; </a></li>
</ul>
Image Credit: Shutterstock

$BTC

Core Scientific, Inc. - Class A Common Stock

CORZ

CRWV

MSFT

CRWV–CORZ Potential Deal Could Unlock $2.8 Billion Hidden Value For Bitcoin Miner, Says Morgan Stanley

TAL Education (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAL#NYSE">TAL</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.36, a high estimate of $16.00, and a low estimate of $10.90. Observing a downward trend, the current average is 18.79% lower than the prior average price target of $15.22. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029278_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
A comprehensive examination of how financial experts perceive TAL Education is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alice Cai</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.54</td>
<td>$13.40</td>
</tr>
<tr>
<td>Linda Huang</td>
<td>Macquarie</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.90</td>
<td>$14.50</td>
</tr>
<tr>
<td>DS Kim</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>DS Kim</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$16.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to TAL Education. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of TAL Education compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of TAL Education's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into TAL Education's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TAL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on TAL Education analyst ratings.</a>
<h2>Discovering TAL Education: A Closer Look</h2>
TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
<h3>Unraveling the Financial Story of TAL Education</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: TAL Education's remarkable performance in 3M is evident. As of 28 February, 2025, the company achieved an impressive revenue growth rate of 42.06%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: TAL Education's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -1.2%, the company may face hurdles in effective cost management.
Return on Equity (ROE): TAL Education's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.19%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): TAL Education's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -0.13%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.09, TAL Education adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess TAL Education: What You Need To Know

Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.2, a high estimate of $17.00, and a low estimate of $6.00. Highlighting a 5.38% decrease, the current average has fallen from the previous average price target of $10.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029265_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Sprinklr among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$10.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Matthew Vanvliet</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Neutral</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Berg</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Elizabeth Porter</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Clark Wright</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$8.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sprinklr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sprinklr compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Sprinklr's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CXM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Sprinklr analyst ratings.</a>
<h2>Discovering Sprinklr: A Closer Look</h2>
Sprinklr Inc is engaged in enabling customer-facing teams, from Customer Service to Marketing, to collaborate across internal silos, communicate across digital channels, and leverage AI to deliver customer experiences at scale all on one unified AI-based platform. It focuses on empowering companies to deliver next-generation, unified engagement journeys that reimagine the customer's experience. Its products include Sprinklr Service, Sprinklr Social, Sprinklr Insights and Sprinklr Marketing. The company operates in the Americas, EMEA, and other countries. It derives maximum revenue from the Americas.
<h3>Breaking Down Sprinklr's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Over the 3M period, Sprinklr showcased positive performance, achieving a revenue growth rate of 4.87% as of 30 April, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Sprinklr's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.76% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Sprinklr's ROE stands out, surpassing industry averages. With an impressive ROE of -0.25%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Sprinklr's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -0.13% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.08.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Sprinklr Stock: A Deep Dive Into Analyst Perspectives (10 Ratings)

Biotech

General

CMND

Clearmind Medicine Adds Hadassah-University Medical Center As New Clinical Site For Phase I/IIa Trial Evaluating CMND-100

In the latest quarter, 8 analysts provided ratings for BeOne Medicines (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONC#NASDAQ">ONC</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $324.38, with a high estimate of $350.00 and a low estimate of $311.00. This current average has decreased by 0.23% from the previous average price target of $325.14. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029256_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of BeOne Medicines by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$311.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$350.00</td>
<td>$348.00</td>
</tr>
<tr>
<td>Gregory Renza</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$312.00</td>
<td>$312.00</td>
</tr>
<tr>
<td>Yaron Werber</td>
<td>TD Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$334.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$317.00</td>
<td>$311.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$348.00</td>
<td>$348.00</td>
</tr>
<tr>
<td>Greg Renza</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$312.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to BeOne Medicines. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of BeOne Medicines compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of BeOne Medicines's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ONC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on BeOne Medicines analyst ratings.</a>
<h2>Get to Know BeOne Medicines Better</h2>
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
<h3>BeOne Medicines's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: BeOne Medicines's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 48.64%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 0.11%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): BeOne Medicines's ROE excels beyond industry benchmarks, reaching 0.04%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): BeOne Medicines's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.02% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: BeOne Medicines's debt-to-equity ratio is below the industry average. With a ratio of 0.28, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 8 Analyst Ratings Have To Say About BeOne Medicines

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has been analyzed by 26 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">13</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">10</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Uber Technologies and provided 12-month price targets. The average target is $95.65, accompanied by a high estimate of $110.00 and a low estimate of $80.00. This current average has increased by 7.04% from the previous average price target of $89.36. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029240_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Uber Technologies among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Gianarikas</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Hold</td>
<td>$84.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$106.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Mark Kelley</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Rob Sanderson</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Ronald Josey</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Lloyd Walmsley</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$107.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Justin Post</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Josh Beck</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$97.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$110.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Tom White</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$98.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Brad Erickson</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Deepak Mathivanan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Justin Patterson</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Doug Anmuth</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>John Blackledge</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$88.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$87.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Uber Technologies. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Uber Technologies compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Uber Technologies's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Uber Technologies's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/UBER/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Uber Technologies analyst ratings.</a>
<h2>About Uber Technologies</h2>
Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food couriers, and shippers with carriers. The firm's on-demand technology platform is currently utilized by traditional cars as well as autonomous vehicles, but could eventually be used for additional products and services, such as delivery via drones or electronic vehicle take-off and landing (eVTOL) technology. Uber operates in over 70 countries, with over 170 million users who order rides or food at least once a month.
<h3>Key Indicators: Uber Technologies's Financial Health</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Positive Revenue Trend: Examining Uber Technologies's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 13.84% as of 31 March, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Industrials sector.
Net Margin: Uber Technologies's net margin is impressive, surpassing industry averages. With a net margin of 15.4%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Uber Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 8.16%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Uber Technologies's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.41% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.51, Uber Technologies adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

UBER

Forecasting The Future: 26 Analyst Projections For Uber Technologies

Mastercard's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) short percent of float has fallen 19.12% since its last report. The company recently reported that it has 4.99 million shares sold short, which is 0.55% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Mastercard Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751029232_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Mastercard has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Mastercard's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Mastercard's peer group average for short interest as a percentage of float is 6.57%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What's Driving the Market Sentiment Around Mastercard?

11 analysts have expressed a variety of opinions on Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Avidity Biosciences, presenting an average target of $67.0, a high estimate of $96.00, and a low estimate of $54.00. This current average has increased by 0.84% from the previous average price target of $66.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1751029229_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Avidity Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Schmidt</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$96.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Andy Chen</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Freeman</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Strong Buy</td>
<td>$65.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$59.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$68.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Keay Nakae</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Avidity Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Avidity Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
For valuable insights into Avidity Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RNA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Avidity Biosciences analyst ratings.</a>
<h2>About Avidity Biosciences</h2>
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
<h3>Avidity Biosciences's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Avidity Biosciences's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -55.6% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Avidity Biosciences's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -7360.01%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Avidity Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -8.41% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Avidity Biosciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -7.66%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.0, Avidity Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>What Are Analyst Ratings?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Avidity Biosciences Through The Eyes Of 11 Analysts

ASTI

Ascent Solar Enters Into Teaming Agreement To Supply US-Based Defense Solutions Provider With Thin-Film Solar Technology Solutions For Upcoming Orbital Applications And Future Missions

Press Releases

Enovix Completes Site Acceptance Testing (SAT) of Fab2

Enovix Secures Landmark Purchase Order for Silicon Batteries

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enovix Corporation- ENVX

Enovix to Release Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025

Glancy Prongay & Murray LLP Announces Investigation of Enovix Corporation (ENVX)

Earnings

Enovix Announces Fourth Quarter and Full Year 2024 Financial Results

Enovix Reports Progress on 2025 Smartphone Launch

Enovix To Acquire Korean Battery Cell Facility to Bolster Manufacturing

Management

Enovix Appoints Ryan Benton as Chief Financial Officer

Enovix Announces First Quarter 2025 Financial Results

ADS-TEC Energy

AMETEK

American Superconductor Corporation - Common Stock

American Superconductor

Array Technologies

Atkore

Acuity

Emerson Electric

EnerSys

Eos Energy Enterprises, Inc. - Common Stock

Eos Energy Enterprises

Eaton Corp

Fluence Energy, Inc. - Class A Common Stock

Fluence Energy

Generac Hldgs

Hubbell

nVent Electric

Nextracker

Preformed Line Products Company - Common Stock

Preformed Line Products

Plug Power

Powell Industries

Rockwell Automation

Regal Rexnord

Sunrun

Shoals Technologies Group, Inc. - Class A Common Stock

Shoals Technologies Gr

Thermon Group Holdings, Inc. Common Stock

Thermon Group Holdings

Vicor

Vertiv Holdings, LLC Class A Common Stock

Vertiv Holdings

JP Morgan

TD Securities

B. Riley Securities

Benchmark

Craig-Hallum

수요일(19일) 미국 주요 지수는 다우존스 산업평균지수와 S&amp;P 500 지수가 각각 0.2% 가까이 상승한 44,627.59포인트 및 6,144.15포인트를 기록하며 상승 마감했다. 나스닥 지수는 0.07% 상승한 20,056.25포인트로 마감했다.



수요일에 소매 투자자와 트레이더들의 주목을 받은 상위 종목은 다음과 같다. 



팔란티어 테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>)



수요일 팔란티어 테크놀로지스는 주가가 10.08% 하락하여 112.06달러에 마감했다. 장중 최고가 125.41 달러, 최저가 108.56 달러였으며 52주 범위는 20.33~125.41달러이다. 팔란티어 주가 하락은 트럼프 행정부가 국방부에 <a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch">상당한 예산 삭감에 대비</a>하라는 지시에 따른 것으로, 팔란티어와 같은 국방 관련 주식에 영향을 미칠 수 있다. 국방부의 예산 삭감은 향후 5년간 매년 8%가 될 것으로 예상된다.



카바나 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)



카바나 주가는 0.95% 하락하여 281.82달러로 마감했다. 장중 최고가는 292.84달러, 최저가는 280.20달러였고, 52주 범위는 48.15~292.84달러다. 이번 하락은 카바나가 예상치를 뛰어넘는 35억 5천만 달러의 매출로 <a href="https://in.benzinga.com/news/earnings/25/02/43831159/carvana-stock-hits-the-brakes-following-q4-earnings-revenue-beat-eps-beat-upbeat-guidance-this-is-just-the-beginning">강력한 4 분기 실적</a>을 보고했음에도 불구하고 발생했다. 또한 주당 56센트의 수익을 보고하여 예상치를 상회했다.



에노빅스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)



에노빅스 주가는 0.27% 소폭 상승하며 11.19달러로 마감했다. 장중 최고가 11.42달러, 최저가 10.76달러를 기록했으며, 52주 범위는 5.70달러에서 18.68달러 사이다. 에노빅스는 <a href="https://in.benzinga.com/news/earnings/25/02/43831159/carvana-stock-hits-the-brakes-following-q4-earnings-revenue-beat-eps-beat-upbeat-guidance-this-is-just-the-beginning">4분기 매출</a>이 972만 달러로 예상치를 상회했다고 발표했다. 그러나 향후 분기에 대한 약세 가이던스는 투자자들의 열정을 약화시켰다.



그랩 홀딩스 (NASDAQ:<a href="https://www.benzinga.com/quote/grab">GRAB)</a>



그랩 홀딩스 주가는 0.75% 상승하여 5.34달러로 마감했다. 장중 최고가는 5.37달러, 최저가는 5.10달러이며 52주 범위는 2.98~5.72달러다. 그랩 주가는 싱가포르의 2025년 예산 발표 이후 50%의 법인세 환급이 기업이 비용 상승에 대처하는 데 도움이 될 수 있다는 소식에 <a href="https://www.benzinga.com/trading-ideas/movers/25/02/43794012/grab-shares-rise-following-singapores-2025-budget-announcement">상승세를 보였다</a>.



테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)



테슬라 주가는 1.82% 상승하여 360.56달러에 마감했다. 장중 최고가 367.34달러, 최저가 353.67달러를 기록했으며, 52주 범위는 138.80달러에서 488.54달러 사이다. 이러한 상승세는 인도에서의 성장을 지원하기 위해 인재를 고용하려는 테슬라의 인도 <a href="https://www.benzinga.com/tech/25/02/43805175/elon-musks-tesla-prepares-for-india-expansion-engineer-confirms-hiring-push-we-are-looking-for-motivated-talent-to-help-us">확장 계획</a> 소식 이후 나타났다.



<a href="https://www.benzinga.com/premarket">벤징가 프리마켓 주요 동향 및 뉴스</a>와 함께 오늘의 거래를 준비하세요.



이미지: Shutterstock 



Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.



독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

월요일(6일) 미국 증시는 S&amp;P 500 지수와 나스닥 지수가 큰 폭으로 상승하며 상승세를 보였다. 기술주 중심의 나스닥 종합 지수는 240포인트 이상 상승하며 1.2% 상승한 19,864.98포인트로 마감했다. S&amp;P 500 지수도 0.55% 상승하며 5,975.38포인트로로 마감했다. 반면 다우존스 산업평균 지수는 0.06% 소폭 하락한 42,706.56포인트로 마감했다.
월요일에 소매 투자자들과 트레이더의 관심을 끌었던 주요 종목은 다음과 같다.
1. 메타 플랫폼스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)
월요일 메타 플랫폼스 주가는 4.23% 급등하여 630.20달러에 마감했다. 주가는 장중 최고가 630.99달러, 최저가 605.62달러를 기록했으며 52주 범위는 352.05~638.40달러다. 이러한 상승은 UFC CEO인 데이나 화이트(Dana White)가 <a href="https://www.benzinga.com/general/social-media/25/01/42833727/dana-white-wanted-elon-musk-mark-zuckerberg-in-cage-fight-now-hes-on-metas-board-of-directors" target="_blank" rel="noopener">메타의 이사회에 합류하면서</a> 나타났다. 이전에 화이트는 일론 머스크와 마크 저커버그 사이의 자선 격투기 대결을 조직하려고 시도한 적이 있다.
2. 트럼프 미디어 &amp; 테크놀로지 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NYSE">DJT</a>)
트럼프 미디어의 주가는 4.48% 상승하여 36.17달러로 마감했다. 주가는 장중 최고가 36.70달러, 최저가 35.08달러를 기록했으며, 52주 범위는 22.55~79.38달러다. 이번 상승은 월요일 미국 의회가 도널드 트럼프 대통령 당선인의 <a href="https://www.benzinga.com/news/25/01/42832156/trump-confirmed-as-president-by-vp-harris-as-former-vp-mike-pence-breathes-easy-this-jan-6" target="_blank" rel="noopener">대선 승리를 공식 인증</a>했다는 소식에 따른 것이다. 이러한 인증은 선거 기간 동안 그의 주요 경쟁자였던 카멀라 해리스가 진행했다.
3. 푸보TV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUBO#NYSE">FUBO</a>)
푸보TV의 주가는 253.85% 급등하여 5.06달러로 마감했다. 주가는 장중 최고가 5.30달러, 최저가 3.05달러를 기록했으며, 52주 범위는 1.10~5.30달러입. 이러한 극적인 상승은 <a href="https://www.benzinga.com/25/01/42816545/fubotv-and-disney-near-merger-to-create-second-largest-digital-tv-provider-shares-soar-report" target="_blank" rel="noopener">디즈니의 훌루 + 라이브 TV</a>와의 합병 발표에 따른 것이다. 합병된 법인은 디즈니가 최대주주가 되어 해당 벤처의 70%를 보유하게 된다.
4. 이노빅스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)
이노빅스 주가는 1.58% 하락하여 12.46달러에 마감했다. 장중 최고가는 13.03달러, 최저가는 12.20달러였고, 52주 범위는 5.70~18.68달러다. 이러한 하락은 말레이시아의 Fab2 제조 라인에 대한 <a href="https://www.benzinga.com/news/global/25/01/42833082/enovix-shares-are-moving-higher-after-the-bell-whats-going-on" target="_blank" rel="noopener">현장 승인 테스트가 완료</a>되었음에도 불구하고 발생했다. 이노빅스는 올해 말부터 대량 생산을 시작할 계획이다.
5. 테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 0.15% 상승하여 411.05달러로 마감했다. 장중 최고가 426.43달러, 최저가 401.70달러를 기록했으며, 52주 범위는 138.80~488.54달러다. 애널리스트인 스티븐 젠가로(Stephen Gengaro)는 향후 출시될 차량 모델과 <a href="https://www.benzinga.com/25/01/42832866/tesla-stock-well-positioned-to-deliver-robust-multi-year-growth-why-analyst-is-raising-price-target-after-deliveries-miss" target="_blank" rel="noopener">완전자율주행(FSD)</a> 라이선스 기회로 인해 다년간 견고한 성장 잠재력을 언급하며 테슬라 목표주가를 상향 조정했다.
벤징가와 함께 <a href="https://editorial.benzinga.com/wp-admin/Premarket%20Movers%20&amp;%20News">하루의 거래를 준비하세요</a>!
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

이노빅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)의 주식은 회사가 말레이시아 <a href="https://www.benzinga.com/pressreleases/25/01/g42831392/enovix-completes-site-acceptance-testing-sat-of-fab2">Fab2</a>의 현장 수용 테스트를 완료했다고 발표한 후 월요일 시간외 거래에서 약 10% 급등했다.
무슨 일이 있었나: 이노빅스(Enovix)는 지난 12월 말에 Fab2의 고용량 제조 라인에 대한 현장 수용 테스트를 완료했다고 밝혔다. 이 배터리 제조 회사는 올해 말 대량 생산을 시작할 계획이다.
현장 수용 테스트는 이 회사의 제조 장비 준비 상태를 검증하며 상업적 규모의 생산이 시작되기 전의 최종 공장 수용 테스트 단계이다. 이노빅스는 이 이정표가 Fab2가 고성능 실리콘 배터리를 대량으로 생산할 수 있도록 완전히 갖추어졌음을 보여준다고 언급했다.
&#8220;SAT의 완료는 Fab2와 이노빅스에 있어 전환점이 된다&#8221;고 라즈 탈루리(Raj Talluri) CEO가 말했습니다.
&#8220;이는 우리 팀의 헌신과 운영 우수성에 대한 우리의 약속을 반영한다. 우리의 최첨단 기술에 대한 고객의 관심이 상당한 만큼, Fab2는 대규모 생산 요구를 충족하면서도 최고의 품질 기준을 유지할 수 있게 해줄 것이다.&#8221;
또한 참고할 사항: <a href="https://www.benzinga.com/25/01/42762224/bev-market-share-will-increase-across-us-china-europe-in-2025-says-sp-global-mobility">2025년까지 배터리 전기차 판매가 30% 급증하여 글로벌 경량차 시장의 17%를 차지할 것이라는 보고서</a>
<h1 class="wp-block-heading">ENVX 주식은 매수하기에 좋은가?</h1>
투자자가 주식이 좋은 매수인지 여부를 결정할 때 몇 가지 선택을 할 수 있다. 벤징가의 주식 인용 페이지에서 확인할 수 있는 가치 평가 지표와 주가 움직임 외에도 — 예를 들어 <a href="https://www.benzinga.com/quote/ENVX">Enovix</a> 페이지와 같은 — 회사가 배당금을 지급하는지 또는 매 분기 자사주를 대량으로 매입하는지와 같은 요소들이 있다.
이것들은 자본 배분 프로그램으로 알려져 있다. 이노빅스는 배당금을 지급하지 않지만, 주주에게 가치를 반환할 수 있는 몇 가지 방법이 있다. 다음 배당금 지급 예정 회사를 확인하고 주식을 보유했을 때 어떤 종류의 수익률을 얻을 수 있는지 알아보려면 벤징가의 <a href="https://www.benzinga.com/calendars/dividends">배당 캘린더</a>를 검색해 보세요.
자사주 매입 프로그램은 분명히 다르며 매우 변동성이 있다. 회사는 매입 프로그램을 승인하고 매입이 승인된 기간 동안 주식을 필요에 따라 매입할 수 있다. <a href="https://www.benzinga.com/quote/ENVX">이노빅스</a>에 대한 최신 뉴스를 살펴보면 회사가 최근에 매입 프로그램을 승인했는지 여부를 확인할 수 있다. 매입 프로그램은 보통 주가에 대한 지지 역할을 하며 수요의 백스톱 역할을 한다.
ENVX 주가 변동: 월요일 <a href="http://benzinga.com/quote/envx" target="_blank" rel="noreferrer noopener">이노빅스의 주식</a>은 시간외 거래에서 9.55% 상승하여 $13.65로 거래되었다.
사진: Piotr Swat via Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

에노빅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)의 주가는 회사가 예상보다 나은 3분기 재무 결과를 보고하고 한 <a href="https://www.benzinga.com/pressreleases/24/10/g41610350/enovix-announces-third-quarter-2024-financial-results">선도적인 스마트폰 회사</a>와의 개발 계약을 발표한 후 화요일 시간외 세션에서 약 6% 상승했다.
<ul>
<li>3분기 매출: 432만 달러, <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noopener" data-google-interstitial="false">예상</a> 411만 달러 대비</li>
</ul>
<ul>
<li>3분기 주당순이익(EPS): 손실 17센트, 예상 손실 20센트 대비</li>
</ul>
&#8220;우리는 3분기 성과에 매우 기쁘다. Fab2는 이제 운영 중이며 고객에게 샘플을 배송하고 있다,&#8221;고 에노빅스의 사장 겸 CEO인 라즈 탈루리(Raj Talluri)가 말했다.
&#8220;우리는 주요 스마트폰 OEM으로부터 2025년 출시 약속을 확보했다. 그리고 EX-2M 및 그 이후의 제품 로드맵에 대한 진전을 이루었다. 2024년 남은 몇 개월 동안의 주요 목표는 고용량 라인에 대한 SAT를 완료하고 EX-2M 샘플을 배송하는 것이다.&#8221;
에노빅스는 4분기 매출이 800만 달러에서 1,000만 달러 사이가 될 것으로 예상하며, 이는 예상 738만 달러 대비 높다. 이 회사는 4분기 조정 손실이 주당 15센트에서 21센트 사이가 될 것으로 예상하며, 이는 주당 20센트 손실 예상치와 비교된다.
놓치지 마세요: <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41573705/enovix-prepares-for-q3-earnings-analyst-sees-potential-squeeze-but-technical-signals-rai">에노빅스가 3분기 실적 발표를 준비하는 중: 분석가는 잠재적 &#8216;스퀴즈&#8217;를 보지만 기술 신호는 경고 신호를 보낸다</a>
스마트폰 OEM 계약: 에노빅스는 &#8220;중국에서 시장 점유율 5위 안에 드는 세계적인 스마트폰 OEM 중 하나와 개발 계약을 체결했다&#8221;고 발표했다.
이 계약에 따라 에노빅스는 특정 스마트폰 모델에 맞춤화된 100% 활성 실리콘 음극 배터리를 개발할 것이다. 이 회사는 맞춤형 배터리의 출시를 2025년 4분기로 목표하고 있다고 밝혔다.
&#8220;회사는 이제 두 개의 주요 스마트폰 OEM과 계약을 맺었으며, IoT 및 전기차 시장에서 추가 판매 모멘텀이 구축되고 있다&#8221;고 이 회사가 말했다.
ENVX 주가 움직임: 에노빅스의 주식은 애프터 마켓에서 4.89% 상승하여 화요일 기준으로 11.15달러에 거래되었다. 마감 후 잠시 13.10달러까지 급등했었다.
사진: Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Contracts

에노빅스의 주식이 시장 마감 후 상승: 무슨 일이?

벤징가는 지난주 <a href="http://www.benzinga.com/trading-ideas" target="_blank" rel="noopener" data-google-interstitial="false">많은 투자자들이 선호하는 주식들</a>의 전망을 조사한 결과를 바탕으로, 주요 뉴스를 요약했다.
S&amp;P 500과 다우 지수가 6주 연속 상승세를 끊고 하락했다. S&amp;P 500은 거의 1% 하락했고, 다우는 2.7% 하락했다. 반면, 나스닥은 7주 연속 상승하며 0.2% 상승하여 사상 최고가를 기록했다. 이는 대형 기술주들의 강력한 실적에 의해 주도되었다.
대선이 다가오면서 투자자들의 조심스러운 태도로 월스트리트는 전반적인 보합세를 보이며 한 주를 보냈다. 재정 정책과 잠재적인 무역 중단에 대한 우려가 여전하다.
국채 수익률의 상승은 다음 정부에 대한 재정적 도전의 시장 기대를 나타냈으며, 이는 <a href="https://www.benzinga.com/markets/equities/24/10/41556896/investors-cautious-with-election-ahead-treasury-yields-surge-further-tesla-surprises-this-week-i" target="_blank" rel="noopener" data-google-interstitial="false">선거 결과와 관계없이</a> 발생하는 일이다.
벤징가는 투자자들 사이에서 가장 인기 있는 주식들에 대한 일일 보고서를 제공한다. 지난주의 가장 긍정적이고 부정적인 뉴스 기사들을 다시 살펴보겠다.
<h3 class="wp-block-heading">강세 뉴스</h3>
<a href="https://www.benzinga.com/author/ananya-gairola" target="_blank" rel="noopener" data-google-interstitial="false">Ananya Gairola</a>의 "<a href="https://www.benzinga.com/news/24/10/41422278/nvidias-new-free-open-source-ai-model-reportedly-outperforms-openais-gpt-4o-anthropics-claude-3-5-so">엔비디아의 새로운 무료 오픈 소스 AI 모델, 오픈AI의 GPT-4o, 앤트로픽의 클로드 3.5 소넷을 초과 성과</a>,"라는 제목의 기사에서, 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)가 라마 3.1-네모트론-70B-인스트럭트(Llama-3.1-Nemotron-70B-Instruct)라는 무료 오픈 소스 AI 모델을 출시하여 주요 벤치마크에서 경쟁사들을 초과한 성과를 보였다고 상세히 설명한다. 이는 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)의 프레임워크를 활용한 AI 소프트웨어 지배력으로의 전략적 전환을 반영한다.
<a href="https://www.benzinga.com/author/khyathi-dalal" target="_blank" rel="noopener" data-google-interstitial="false">Khyathi Dalal</a>의 &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41427013/dogecoin-up-28-over-the-past-week-and-major-bitcoin-move-could-send-it-beyond-0-50-says-ve">지난주 도지코인이 28% 상승하고 주요 비트코인 움직임이 0.50달러 이상으로 보낼 수 있다</a>,&#8221;의 기사에서는 두 명의 트레이더가 도지코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)이 0.50달러 이상으로 급등할 것이라고 예측한 내용을 강조한다. 이는 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)이 중요한 수준을 돌파할 경우 발생하며, 역사적 추세와 자금 흐름 지표가 밈 코인의 상승 모멘텀을 지원한다.
<a href="https://www.benzinga.com/author/surbhi-jain" target="_blank" rel="noopener" data-google-interstitial="false">Surbhi Jain</a>의 &#8220;<a href="https://www.benzinga.com/markets/esg/24/10/41426513/plug-power-evgo-enovix-analyst-clean-tech-picks-for-navigating-election-exposure-hedging-uncertainty">플러그 파워, EV고, 에노빅스: 선거 노출 탐색 및 불확실성 헤징을 위한 애널리스트 클린 테크 추천</a>,&#8221;의 기사는 JP모건의 한 애널리스트가 선거 관련 시장 변동성을 탐색하기 위한 추천을 다루고, 플러그 파워(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>)와 EV고(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>)를 잠재적인 상승세로 추천하며, 에노빅스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)는 소비자 전자 제품 및 비미국 시장에 대한 집중으로 인해 안전한 헤지로 제안한다.
지난주 추가적인 강세 의견은 다음 링크를 통해 확인:
&#8211; <a href="https://www.benzinga.com/government/24/10/41504166/palantir-stock-moves-higher-on-l3harris-partnership-what-you-need-to-know">팔란티어 주식은 L3해리스 파트너십으로 상승했습니다: 알아야 할 사항</a> 
&#8211; <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41434510/us-economy-eyes-3-4-growth-in-q3-is-a-soft-landing-turning-into-a-reacceleration">미국 경제는 3.4% 성장률을 예상: 소프트 랜딩이 재가속화로 전환되고 있?</a> 
&#8211; <a href="https://www.benzinga.com/top-stories/24/10/41461461/exclusive-soundhound-ai-wants-to-voice-enable-the-world-for-effortless-conversations-between-people">독점: 사운드하운드 AI는 사람들, 제품 간의 원활한 대화를 위한 &#8216;음성 지원 세상을&#8217; 원한다</a>
<h3>약세 뉴스</h3>
<a href="https://www.benzinga.com/author/piero-cingari" target="_blank" rel="noopener">Piero Cingari</a>의 &#8220;<a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41431485/goldman-sachs-predicts-bleak-long-term-s-p-500-returns-as-market-concentration-hits">골드만삭스는 S&amp;P 500의 장기 수익률이 &#8216;100년 만에 최고 수준의 시장 집중&#8217;으로 암울할 것이라고 예측</a>,&#8221;이란 기사에서 골드만삭스가 향후 10년 동안 S&amp;P 500의 연평균 수익률이 3%에 불과할 것이라고 예측하며, 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)과 다른 기업들에 의해 주도되는 극단적인 시장 집중이 과거 10년간 13%의 수익률에 비해 성장을 심각하게 제한할 수 있다고 경고한다.
<a href="https://www.benzinga.com/author/chris-katje" target="_blank" rel="noopener">Chris Katje</a>의 &#8220;<a href="https://www.benzinga.com/news/24/10/41505138/lucid-ceo-throws-cold-water-on-teslas-robotaxi-vision-says-self-driving-cars-wont-happen-till-the-20">루시드 CEO는 테슬라의 로보 택시 비전에 찬물을 끼얹으며 자율주행차는 &#8216;2030년대까지는 불가능할 것&#8217;이라고 주장</a>,&#8221;이란 기사에서는 피터 롤린슨( Peter Rawlinson)이 자율주행차의 즉각적인 미래에 대한 의구심을 강조하며, 2030년대까지는 광범위한 배치가 불가능할 것이라고 예측하고 테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)와 일론 머스크의 자율주행 야망을 비판했다.
<a href="https://www.benzinga.com/author/aniket-verma" target="_blank" rel="noopener">Aniket Verma</a>의 &#8220;<a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41478505/peter-schiff-predicts-a-bloodbath-for-microstrategy-stock-calls-it-the-most-overvalued-on-">피터 쉬프는 마이크로스트레티지 주식에 대한 &#8216;대량 매도&#8217;를 예측하며, 그것을 MSCI 세계 지수에서 가장 고평가된 것으로 칭했다</a>,&#8221;라는 기사에서 피터 쉬프는 마이크로스트레티지(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>)가 MSCI World Index에서 상당히 고평가되었다고 경고하며, 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 보유와 투기적 전략에 대한 의존성으로 인해 극적인 폭락이 예상된다고 보도했다.
더 많은 약세 의견은 다음 링크를 통해 확인:
&#8211; <a href="https://www.benzinga.com/news/24/10/41517027/five-us-banks-face-billions-in-losses-as-silvers-price-spike-hits-short-sellers-hard-report">5개 미국 은행은 은 가격 급등이 공매도 투자자에게 큰 타격을 주면서 수십억 달러의 손실을 입을 위기에 직면: 보고서</a> 
&#8211; <a href="https://www.benzinga.com/news/24/10/41506422/ozempic-and-wegovy-maker-novo-nordisk-asks-fda-to-halt-production-of-compounded-fat-loss-drugs-due-to-their-inherent-complexity">오젬픽과 위고비 제조사인 노보 노디스크가 복합 지방 감소 약물의 생산 중단을 FDA에 요청</a> 
&#8211; <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41460886/rivian-analyst-cuts-estimates-on-demand-concerns-warns-softer-production-delivery-trends-jeopardize-growth-stock-multiple">리비안 애널리스트가 수요 우려로 추정치를 하향 조정</a>
모든 최신 뉴스와 거래 아이디어를 확인하려면 <a href="https://twitter.com/Benzinga">Benzinga를 트위터에서 팔로우하세요</a>.
Image created using artificial intelligence via Midjourney.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Cryptocurrency

$DOGE

AAPL

EVGO

MSTR

NVDA

PLUG

벤징가 불스 앤 베어스: 엔비디아, 테슬라, 마이크로스트레티지, 플러그 파워 및 도지코인

수요일에는 미국 주요 지수가 혼조세를 보였다. 다우존스 산업평균지수는 0.2% 오른 37,903.29에 장을 마감했고, S&amp;P 500 지수는 0.3% 하락한 5,018.39에 마감했다. 마찬가지로 나스닥도 0.33% 하락한 15,605.48로 마감했다.
이들은 수요일 소매 트레이더와 투자가들의 관심을 끈 상위 주식들이다:
카바나(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)
카바나의 주식은 강한 1분기 실적 발표 후 5.03% 상승하여 87.09달러로 마감했습니다. 이 회사는 1분기 매출이 30억 6,100만 달러로 <a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">컨센서스 추정치</a>인 26억 7,300만 달러를 넘어섰다. 이 회사는 조정 EBITDA를 2억 3,500만 달러로 보고했다. 카바나는 분기에 전년 동기 대비 16% 증가한 91,878대의 차량을 판매했다.
에노빅스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)
에노빅스의 주식은 3.99% 상승한 6.51달러에 마감했다. 주당 31센트의 분기별 손실로 분석가 콘센서스 추정치를 미달했지만, 회사는 1분기 527.2만달러의 <a href="https://www.benzinga.com/news/earnings/24/05/38567768/enovix-stock-soars-on-blockbuster-q1-sales">대박 매출</a>을 발표했으며, 이는 지난해 동기 대비 큰 증가이다.
참고 자료: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38519395/goldman-sachs-tempers-investor-excitement-on-tesla-self-driving-not-yet-an-eyes-off?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">골드만삭스, 테슬라 자율 주행 기술 투자가들의 흥분 진정</a>
화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)
화이자의 주식은 6.09% 상승한 27.18달러에 마감했다. 이 회사는 전년 동기 대비 33% 감소에도 불구하고 1분기 조정 주당 순이익(EPS)를 82센트로 보고하여 컨센서스인 54센트를 상회했다. 전년 동기 대비 매출은 <a href="https://www.benzinga.com/general/biotech/24/05/38554240/pfizer-embraces-direct-to-consumer-model-for-covid-antiviral-says-comirnaty-revenues-continue-to-" target="_blank" rel="noopener">20%</a> 감소한 149억 달러로 여전히 컨센서스인 142억 달러를 웃돌았다.
니오(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>)
니오의 주가는 11.65% 상승한 5.27달러에 마감했다. 이 회사는 <a href="https://www.benzinga.com/markets/equities/24/05/38547416/why-nio-shares-are-gaining-today" target="_blank" rel="noopener">4월 차량</a> 인도량이 15,620대로, 전년 대비 134.6%의 증가를 기록했다.
테슬라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>)
테슬라의 주가는 중국에서 자율 주행 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/05/38542475/teslas-stock-could-rise-by-up-to-24-if-ev-giants-china-fsd-rollout-succeeds-says-fu">소프트웨어 롤아웃</a>의 소식에도 불구하고 1.79% 하락한 180달러에 마감했다.
Jirapong Manustrong 쉐터스톡의 사진
Benzinga의 탑 프리마켓 움직임과 뉴스와 함께 트레이딩을 준비하십시오.
<div style="font-family: 'Lato', sans-serif;">
<hr style="border: 0; height: 5px; background: #225aa9;" />
<div style="background-color: #f5f5f5; background-position: center; background-size: cover; justify-content: center;"></div>
<hr style="border: 0; height: 1px; background: #225aa9;" />
<hr style="border: 0; height: 5px; background: #225aa9;" />
</div>

수요일 주목받은 5개의 주식: 카바나, 에노빅스, 화이자, 니오, 테슬라

미국 배터리 제조업체인 에노빅스 코퍼레이션(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVX#NASDAQ">ENVX</a>)은 수요일 시장 마감 후 1분기 재무 결과를 보고했다. <a href="https://www.benzinga.com/pressreleases/24/05/g38563755/enovix-announces-first-quarter-2024-financial-results" target="_blank" rel="noopener">주요 내용</a>을 살펴보자.
세부 내용 (The Details): 에노빅스는 주당 31센트의 분기 손실을 보고했는데, 이는 분석가들의 합의 손실 추정치인 29센트를 6.9%나 하회한 것이다.
분기별 매출은 527만 2,000달러로 애널리스트 컨센서스 추정치 377만 9,000달러를 39.53% 앞섰고 지난해 같은 기간 매출 2만 1,000달러보다 크게 증가했다.
에노빅스는 매출 증가와 유리한 제품 혼합 덕분에 회사가 역사상 처음으로 비GAAP 총마진을 달성하는 데 도움이 되었다고 밝혔다.
"우리는 Fab2가 배터리 생산을 시작할 예정이고 최종 EX-1M 배터리가 2분기에 샘플링될 준비가 되어 있는 2024년에 강력한 출발을 시작했다. 선도적인 OEM들이 100% 활성 실리콘 양극을 사용할 수 있는 고에너지 배터리 셀을 최초로 시장에 출시하기를 열망함에 따라 우리의 고객 관계는 더욱 강력해졌다"고 이 회사가 말했다.
또한 이 회사는 단위 수량 기준으로 세계 5대 스마트폰 OEM 중 하나와 개발 계약을 체결했다고 <a href="https://www.benzinga.com/pressreleases/24/05/g38563754/enovix-reaches-development-agreement-with-a-leading-smartphone-oem" target="_blank" rel="noopener">발표</a>했다.
&#8220;우리는 EX-1M을 시작으로 우리의 실리콘 배터리가 차세대 스마트폰에 제공할 수 있는 가치와 경쟁 우위를 강조하면서 공식 개발 계약을 체결함으로써 최고 고객 중 한 곳과의 협력을 더욱 발전시켰다는 사실을 발표하게 되어 매우 기쁘다&#8221;고 에노빅스의 사장이자 최고경영자(CEO)인 라지 탈루리 박사(Dr. Raj Talluri)가 말했다.
전망 (Outlook): 에노빅스는 2분기 매출이 300만~400만 달러, 조정 EBITDA 손실이 2,600만~3,200만 달러, 비GAAP 손실이 주당 22~28센트일 것으로 예상한다.
ENVX 주가 움직임: <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>에 따르면, 수요일 시간 외거래에서 에노빅스의 주식은 21.66% 급등한 7.92달러에 거래되었다.
관련 뉴스: <a href="https://www.benzinga.com/news/earnings/24/05/38555359/whats-going-on-with-super-micro-stock-after-earnings">슈퍼 마이크로 주식은 실적 발표 이후에 무슨 일?</a>
사진: Enovix Corporation 제공

Comments

Enovix

뉴스

에 대한 최신 뉴스 Enovix (NASDAQ:ENVX) 주식

목요일, 2월 20, 2025

화요일, 1월 07, 2025

화요일, 10월 29, 2024

토요일, 10월 26, 2024

목요일, 5월 02, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌